Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market

Executive Summary

The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will spur commercial viability for medical treatment of the condition.


Related Content

Orexigen Follows Through On Warning It May Have To Liquidate
If Orexigen Disappears, Who's Left In The Obesity Market?
Advantage Novo As Victoza Gets CV Benefit Okay in Europe
Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts